Angiogenic Switch in Tumor Development: A Review of Mechanisms and Therapies

Artificial Intelligence is entering a new era in oncology. At #ESMO25, several studies highlighted how AI-based pathology, imaging, and multiomic analyses can predict treatment benefit and guide clinical decision-making across tumor types. In the AtezoTRIBE study, AI-driven pathology identified patients who truly benefited from adding atezolizumab to FOLFOXIRI + bevacizumab — 📈 Median PFS: 13.3 vs 11.5 months 📈 Median OS: 46.9 vs 24.7 months Only AI-biomarker–high patients derived benefit (HR for OS 0.54). Similar results were confirmed in AVETRIC, while NERO, AEGEAN, and CROWN demonstrated how combining AI-based imaging, ctDNA, and genomic data can refine response prediction in mesothelioma and lung cancer. 💡 These studies mark a significant step toward data-driven precision oncology, where algorithms complement clinical expertise to personalise care and minimise toxicity. #OncoDaily #OncoAlert #OncoLive #ClinicalResearch #ClinicalTrials #PrecisionOncology #ESMO25

"MedExplora Weekly" 🧠 World Neuroendocrine Tumors Awareness Month Neuroendocrine tumors (NETs) are often slow-growing but notoriously elusive, leading to late diagnoses. Current therapies, such as somatostatin analogs and the targeted radiotherapy Lutetium-177 dotatate (Lu-177-DOTA-TATE), work by binding to somatostatin receptors on tumor cells and delivering localized radiation to control tumor growth. Recent research has taken this further: combining Lu-177-DOTA-TATE with triapine, a ribonucleotide reductase inhibitor that blocks DNA synthesis, significantly reduced tumor burden in preclinical NET models. This combination could enhance the effectiveness of radionuclide therapy and open new doors for patients with advanced or treatment-resistant disease. 🧬 Precision oncology is steadily turning NETs from rare and deadly into manageable conditions. Post Designer: Fatima Jamal Scientific Writer: Simon Mikaelian Further Reading: 1. https://lnkd.in/ecznwMvC #Medexplora #Neuroendocrine #Oncology #Radiotheranostics #PrecisionMedicine #MedicalInnovation #Research #Medexploraweekly

Tumor organoid morphology can predict survival and treatment response in oral squamous cell carcinoma (OSCC) — before therapy begins! This innovative study (published in Nature Communications, Oct 2025) generated patient-derived organoids (PDOs) from 42 OSCC cases and classified them into compact vs. loose morphologies via AI-assisted imaging. Key findings: Compact PDOs: Linked to poorer overall survival (HR 3.2) and chemoradiation resistance. Loose PDOs: Stronger response to cisplatin + 5-FU; better prognosis. Predictive Power: Morphology outperformed TNM staging and HPV status in risk stratification. Translational Ready: Non-invasive, rapid (7–10 days), integrates with routine biopsy workflow. Implication? Move beyond genomics — organoid phenotyping enables true precision oncology: tailor neoadjuvant chemo, escalate/de-escalate radiation, and counsel patients early. Are you using PDOs in H&N cancer yet? What’s your take on phenotypic biomarkers? Read here - https://lnkd.in/gngv7Dkz #HeadAndNeckCancer #OSCC #PrecisionOncology #TumorOrganoids #AIinMedicine

🔴 Exosome Diagnostics: Unlocking Liquid Biopsy for Precision Oncology 💦 Liquid biopsy is evolving - exosomes in biofluids are reshaping the future of non-invasive cancer diagnostics.  🔀 Advanced microfluidics and biosensors now isolate nanoscale vesicles packed with molecular signals that reflect real-time tumor dynamics.  🤖 AI/ML-driven analytics (emerging in research) help decode exosome cargo heterogeneity, enabling precise staging and monitoring.    👉 Clinical trials increasingly validate these workflows for multi-cancer early detection and personalized care.  🤲 Together, lab and digital innovation are driving high-precision, accessible oncology. 📚 Reference – Li J, Wang A, Guo H, et al. "Exosomes: innovative biomarkers leading the charge in non-invasive cancer diagnostics", Theranostics, 2025.  🔗 https://lnkd.in/dyq54hYF #Diagnostics #LiquidBiopsy #LabInnovation #CancerDetection #Biomarkers --- 👨🏻🦱 I’m Biagio Ferraro — after 15+ years in IVD, my passion for innovation is now leading me to explore the world of digital transformation 👇 🌐 https://lnkd.in/dhJvbXVp

🧠 PSMA PET/CT & ¹⁷⁷Lu-PSMA Therapy: A New Era in Prostate Cancer Care The integration of PSMA PET/CT 🔍 and ¹⁷⁷Lu-PSMA therapy 💉 has transformed how we detect, stage, and treat prostate cancer — bringing the theranostic revolution into clinical reality. 💡 Key Insights: • High Sensitivity & Precision: PSMA PET/CT detects microscopic disease often missed by conventional imaging — enhancing staging and treatment planning. • Theranostic Power: “See & Treat” — the same molecular target used for both imaging and therapy ensures seamless patient management. • Clinical Benefits: ¹⁷⁷Lu-PSMA therapy achieves remarkable PSA decline 📉, tumor shrinkage, pain relief, and improved quality of life 🌿. • Personalized Medicine: Enables tailored therapy and precise response assessment, guiding decisions in advanced prostate cancer management. 🔬 As evidence grows, PSMA-based theranostics are redefining prostate cancer care — uniting diagnosis and therapy through molecular precision. 📖 Reference: Nishiyama Y et al., Clinical Nuclear Medicine, 2024; 49(6): e349–e351. 🔗 DOI: https://lnkd.in/dbQaMvck #PSMAPET #Lu177PSMA #Theranostics #ProstateCancer #NuclearMedicine #Radiology #MolecularImaging #TargetedTherapy #PrecisionOncology #PersonalizedMedicine #Vision2030

🧬 Novel tissue-agnostic biomarker approaches could improve response to immunotherapy At #ESMO25 (Berlin, 17–21 October), several studies explored the next frontier of immunotherapy personalization — the development of tumor-agnostic biomarkers that go beyond PD-L1 or MSI-H. 🔹 Composite biomarkers combining Tumor Mutational Burden (TMB) and Tumor-Infiltrating Lymphocytes (TIL) show strong predictive value for response. 🔹 dMMR/MSI-H subtypes reveal that not all mismatch repair deficiencies yield equal benefit from immune checkpoint blockade. 🔹 HLA loss of heterozygosity (LOH) emerges as a critical mechanism of immune escape and therapeutic resistance. 🔹 Computational pathology (CPATH) using AI-based slide analysis can predict genomic evolution and metastatic potential. Together, these findings mark a step toward precision immunotherapy that transcends tissue and tumor type.

How do region-specific markers enhance colorectal cancer screening? 🧬   New stem cell markers NOX1 and NPY1R enable precise tumor identification.   These markers distinguish between caecum and distal colon tumors, allowing for targeted screening approaches and reduced false positives. By understanding tumor origins, healthcare systems can optimize resources while improving early detection capabilities.   Click the link in the comments to explore the research findings! 🔬 #SyenzaInsights #ColorectalCancer #PrecisionMedicine #CancerResearch

What makes tumors in different colon regions unique? 🤔   Singapore scientists reveal crucial findings in colorectal cancer markers.   The discovery that NOX1 marks caecum stem cells while NPY1R identifies distal colon cells helps explain varying tumor behaviors. This research could significantly improve how we screen, diagnose, and treat colorectal cancer, currently the world's third most common malignancy.   Click the link in the comments to understand this important advancement! 💡 #SyenzaInsights #CancerCare #HealthcareInnovation #BiomarkerResearch

Radiomics in preclinical imaging research: methods, challenges and opportunities Radiomics is increasingly used in cancer treatment to predict outcomes and response to therapy: AI-driven radiomics shows promise in stratifying patients, guiding treatment decisions, and assessing treatment response Radiomics-based analyses are increasingly being applied to clinical studies. Radiomic features can be correlated with markers of disease severity or treatment success to improve early detection of disease and develop predictive models for therapeutic response. While radiomics has similar potential in preclinical research, its use in this context entails unique challenges. This paper provides an overview of the current state of radiomics in preclinical imaging, methodologies, challenges and future prospects. https://lnkd.in/gYuariEj